{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-008139","form_type":"8-K","ticker":"ALLR","cik":"0001860657","company_name":"Allarity Therapeutics, Inc.","filed_at":"2025-03-18T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.356812+00:00","generated_at":"2026-05-24T14:34:01.445013+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Allarity reports Phase 2 data for stenoparib in advanced ovarian cancer; durable benefit in platinum-resistant patients","bullets":["5 of 15 patients stayed on therapy >4 months; 1 had confirmed complete response lasting >10 months.","2 patients remain on therapy >17 months; patient with primary platinum-refractory disease remained >40 weeks.","Stenoparib well-tolerated with no bone marrow toxicity typical of first-generation PARP inhibitors.","Clinical benefit seen in BRCA wild-type patients, supporting dual PARP/Wnt pathway inhibition.","New Phase 2 protocol announced focusing on platinum-resistant patients with single prior chemo line."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-008139","json":"https://secwatch.observer/filing/0001437749-25-008139.json","markdown":"https://secwatch.observer/filing/0001437749-25-008139.md","text":"https://secwatch.observer/filing/0001437749-25-008139.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925008139/0001437749-25-008139-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1860657/000143774925008139/allr20250317_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T14:34:01.445013+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}